登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-051 深圳市尚荣医疗股份有限公司 关于参加2025年度深圳辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 2025年11月18日 为进一步加强与投资者互动交流，深圳市尚荣医疗股份有限公司（以下简称"公司"）将参加由深圳证监 局和中证中小投资者服务中心指导、深圳上市公司协会与深圳市全景网络有限公司联合举办的"2025年 度深圳辖区上市公司投资者网上集体接待日活动" ，现将有关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信 公众号：全景财经，或下载全景路演APP,参与本次互动交流，活动时间为2025年11月20日（星期四） 14:30至17:00。届时公司高管将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权激 励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 深圳 ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-051 深圳市尚荣医疗股份有限公司 关于参加 2025 年度深圳辖区上市公司投资者 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP, 参与本次互动交流，活动时间为2025年11月20日（星期四）14:30至17:00。届时 公司高管将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权 激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 资者踊跃参与！ 特此公告。 深圳市尚荣医疗股份有限公司 董 事 会 2025年11月18日 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者互动交流，深圳市尚荣医疗股份有限公司（以下简称 "公司"）将参加由深圳证监局和中证中小投资者服务中心指导、深圳上市公司 协会与深圳市全景网络有限公司联合举办的"2025年度深圳辖区上市公司投资 者网上集体接待日活动" ，现将有关事项公告如下： ...

Core Viewpoint - The financial performance of Shangrong Medical (002551) shows significant declines in revenue and profit, indicating potential challenges in the medical device industry [3]. Financial Performance - As of November 12, 2025, Shangrong Medical's stock closed at 4.08 yuan, with a slight increase of 0.25% and a trading volume of 127,400 hands, amounting to a total transaction value of 51.94 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 225 million yuan, a year-on-year decrease of 39.25%, and a net profit attributable to shareholders of -27.37 million yuan, a decline of 4004.28% [3]. - For the first three quarters of 2025, the company's main revenue was 754 million yuan, down 24.85% year-on-year, with a net profit of -35.13 million yuan, a decrease of 338.5% [3]. Market Position - Shangrong Medical's total market capitalization is 3.45 billion yuan, significantly lower than the industry average of 11.669 billion yuan, ranking 124th in the industry [3]. - The company's net asset value stands at 2.73 billion yuan, compared to the industry average of 3.893 billion yuan, also ranking 124th [3]. - The company's gross margin is 14.35%, which is substantially below the industry average of 51.22%, ranking 119th [3]. Capital Flow - On November 12, 2025, the net inflow of main funds was 1.23 million yuan, accounting for 2.37% of the total transaction value, while retail investors experienced a net outflow of 1.19 million yuan, representing 2.28% of the total transaction value [1][2]. - Over the past five days, the main funds showed fluctuating trends, with a peak net inflow of 3.06 million yuan on November 11, 2025, and a significant net outflow of 3.57 million yuan on November 7, 2025 [2].

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase of 1.5% on November 10, 2025, closing at 4.05 yuan, despite facing significant declines in revenue and profit in recent quarters [1][3]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [3]. - The net profit attributable to shareholders was -35.13 million yuan, representing a year-on-year decline of 338.5% [3]. - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, with a net profit of -27.37 million yuan, a staggering decline of 4004.28% [3]. - The company’s debt ratio stands at 23.31%, with an investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [3]. Market Position - Shangrong Medical's total market capitalization is 3.424 billion yuan, significantly lower than the industry average of 11.616 billion yuan, ranking 102 out of 124 in the medical device industry [3]. - The company has a negative price-to-earnings ratio of -73.12, compared to the industry average of 62.58, indicating poor profitability [3]. - The gross margin is reported at 14.35%, which is substantially below the industry average of 51.22%, ranking 119 out of 124 [3]. Capital Flow Analysis - On November 10, 2025, the net inflow of main funds was 1.90 million yuan, accounting for 3.19% of the total transaction amount, while retail investors saw a net inflow of 1.99 million yuan, making up 3.33% [1][2]. - In contrast, speculative funds experienced a net outflow of 3.89 million yuan, representing 6.52% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with notable outflows from speculative funds on several days [2].

Core Viewpoint - 尚荣医疗 (002551) has shown a decline in key financial metrics, with significant drops in revenue and net profit for the first three quarters of 2025, indicating potential challenges in the medical device industry [2]. Financial Performance - The total revenue for the first three quarters of 2025 was 7.54 billion yuan, a year-on-year decrease of 24.85% [2]. - The net profit attributable to shareholders was -351.25 million yuan, down 338.5% year-on-year [2]. - The third quarter alone saw a revenue of 2.25 billion yuan, a decline of 39.25% compared to the same quarter last year [2]. - The net profit for the third quarter was -273.67 million yuan, a staggering drop of 4004.28% year-on-year [2]. - The company reported a gross margin of 14.35%, significantly lower than the industry average of 51.22% [2]. Market Position - 尚荣医疗's total market capitalization is 3.374 billion yuan, compared to the industry average of 11.464 billion yuan, ranking 101 out of 124 in the industry [2]. - The company has a net asset value of 2.73 billion yuan, which is below the industry average of 3.893 billion yuan, ranking 57 out of 124 [2]. - The price-to-earnings ratio (P/E) is -72.03, indicating negative earnings, while the industry average is 62.26 [2]. - The return on equity (ROE) stands at -1.34%, compared to the industry average of 0.15%, ranking 107 out of 124 [2]. Capital Flow - On November 7, 2025, the stock closed at 3.99 yuan, with a turnover rate of 1.56% and a trading volume of 95,500 hands, amounting to a total transaction value of 38.08 million yuan [1]. - The net outflow of main funds was 3.57 million yuan, accounting for 9.39% of the total transaction value, while retail investors saw a net inflow of 4.48 million yuan, representing 11.76% of the total [1].

Core Viewpoint - 尚荣医疗 (002551) has shown a slight increase in stock price but continues to face significant financial challenges, with declining revenues and profits in recent quarters [1][2]. Financial Performance - As of November 5, 2025, 尚荣医疗's stock closed at 4.04 yuan, up 1.0%, with a trading volume of 121,200 hands and a transaction value of 48.81 million yuan [1]. - In the first three quarters of 2025, the company's main revenue was 754 million yuan, a year-on-year decrease of 24.85% [2]. - The net profit for the same period was -35.13 million yuan, a decline of 338.5% year-on-year [2]. - The third quarter alone saw a revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a drop of 4004.28% [2]. Market Position - 尚荣医疗's total market value is 3.416 billion yuan, significantly lower than the industry average of 11.527 billion yuan, ranking 102 out of 124 in the medical device industry [2]. - The company's net asset value is 2.73 billion yuan, compared to the industry average of 3.893 billion yuan, also ranking 57 out of 124 [2]. - The price-to-earnings ratio (P/E) is -72.93, while the industry average is 60.86, indicating a poor profitability outlook [2]. Profitability Metrics - 尚荣医疗's gross margin stands at 14.35%, significantly below the industry average of 51.22%, ranking 119 out of 124 [2]. - The net profit margin is -4.6%, compared to the industry average of 9.57%, ranking 103 out of 124 [2]. - Return on equity (ROE) is -1.34%, while the industry average is 0.15%, ranking 107 out of 124 [2].

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase, but the company is facing significant financial challenges, including declining revenues and profits [1][3]. Financial Performance - As of November 3, 2025, Shangrong Medical's stock closed at 4.01 yuan, up 1.01% with a trading volume of 13.37 million shares and a total transaction value of 53.36 million yuan [1]. - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a year-on-year decrease of 24.85% [3]. - The net profit attributable to shareholders was -35.13 million yuan, a year-on-year decline of 338.5% [3]. - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a decrease of 4004.28% [3]. Market Position - Shangrong Medical's total market capitalization is 3.39 billion yuan, significantly lower than the industry average of 11.617 billion yuan, ranking 101 out of 124 in the medical device industry [3]. - The company's net assets stand at 2.73 billion yuan, compared to the industry average of 3.893 billion yuan, also ranking 57 out of 124 [3]. - The company has a negative price-to-earnings ratio of -72.39, while the industry average is 63.42, indicating poor profitability [3]. Profitability Metrics - The gross margin for Shangrong Medical is 14.35%, significantly lower than the industry average of 51.22%, ranking 119 out of 124 [3]. - The net margin is -4.6%, compared to the industry average of 9.57%, ranking 103 out of 124 [3]. - Return on equity (ROE) is -1.34%, while the industry average is 0.15%, indicating underperformance [3]. Capital Flow - On November 3, 2025, the net outflow of main funds was 2.0163 million yuan, accounting for 3.78% of the total transaction value [1][2]. - Retail investors showed a net inflow of 7.5863 million yuan, representing 14.22% of the total transaction value [1][2].

Core Insights - The stock of Shangrong Medical (002551) closed at 3.97 yuan on October 31, 2025, with a rise of 2.32% and a trading volume of 170,400 hands, amounting to a transaction value of 67.33 million yuan [1][2] Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decline of 24.85% [3] - The net profit attributable to shareholders was -35.13 million yuan, a year-on-year decrease of 338.5% [3] - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a decline of 4004.28% [3] - The company’s gross margin stood at 14.35%, significantly lower than the industry average of 51.22% [3] Market Position - Shangrong Medical's total market capitalization is 3.357 billion yuan, which is below the industry average of 11.561 billion yuan [3] - The company ranks 124th in the medical device industry based on key financial metrics such as net profit and return on equity (ROE) [3] - The price-to-earnings ratio (P/E) is -71.67, indicating negative earnings, while the price-to-book ratio (P/B) is 1.3, which is better than the industry average of 3.93 [3] Capital Flow Analysis - On October 31, 2025, the net outflow of main funds was 1.67 million yuan, accounting for 2.48% of the total transaction value [1][2] - Retail investors showed a net inflow of 538,700 yuan, representing 0.8% of the total transaction value [1][2] - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from main funds on several days [2]

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a decline in both price and financial performance, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of October 30, 2025, Shangrong Medical's stock closed at 3.88 yuan, down 1.27% with a trading volume of 135,400 shares and a total transaction value of 52.87 million yuan [1]. - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a year-on-year decrease of 24.85%, and the net profit attributable to shareholders was -35.13 million yuan, a decline of 338.5% [3]. - In Q3 2025 alone, the company reported a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a decrease of 4004.28% [3]. Market Position - Shangrong Medical's total market capitalization is 3.281 billion yuan, significantly lower than the industry average of 11.424 billion yuan, ranking 124th in the industry [3]. - The company's net asset value stands at 2.73 billion yuan, compared to the industry average of 3.893 billion yuan, also ranking 124th [3]. - The company's gross profit margin is 14.35%, which is substantially below the industry average of 51.22%, ranking 119th [3]. Capital Flow - On October 30, 2025, the net inflow of main funds was 350,500 yuan, accounting for 0.66% of the total transaction value, while retail investors saw a net inflow of 2.98 million yuan, representing 5.64% of the total [1][2]. - Over the past five days, the stock has experienced significant fluctuations in capital flow, with notable net outflows from main and speculative funds on several days [2].

Core Insights - The company reported a significant decline in revenue and net profit for the third quarter of 2025, with total revenue at 754 million yuan, down 24.85% year-on-year, and a net loss of 35.13 million yuan, a decrease of 338.5% compared to the previous year [1] Financial Performance - Total revenue for Q3 2025 was 225 million yuan, reflecting a 39.25% year-on-year decline [1] - The gross profit margin decreased to 14.35%, down 9.38% year-on-year, while the net profit margin turned negative at -4.6%, a drop of 348.03% [1] - The total of selling, administrative, and financial expenses reached 113 million yuan, accounting for 15.03% of total revenue, which is an increase of 46.75% year-on-year [1] - Earnings per share fell to -0.04 yuan, a decrease of 339.08% year-on-year, and operating cash flow per share was 0.14 yuan, down 39.5% [1] Debt and Cash Flow - The company has a healthy cash position, with cash assets reported as stable [4] - The ratio of operating cash flow to current liabilities over the past three years averaged only 17.24%, indicating potential liquidity concerns [4] - Accounts receivable have reached 2048.22% of profit, suggesting issues with collection and cash flow management [4] Business Strategy - The company is focusing on hospital service-related businesses and product expansion strategies, with plans to allocate working capital towards production, research and development, and channel development [5]